Breakthrough Candida infections in patients receiving voriconazole

Keyphrases

• Voriconazole 100%
• Candida Infection 100%
• Twice Daily 30%
• Drug Interactions 20%
• Efavirenz 20%
• Phenytoin 20%
• Thrush 20%
• Therapeutic Efficacy 10%
• Treatment Dose 10%
• High Dose 10%
• HIV Infection 10%
• Older Women 10%
• CYP2C9 10%
• Tenofovir 10%
• Systemic Lupus Erythematosus 10%
• Cytochrome P450 3A4 (CYP3A4) 10%
• Breakthrough Infection 10%
• 50 Years Old 10%
• Serum Concentration 10%
• Older Men 10%
• Systematic Evaluation 10%
• Unknown Origin 10%
• Azithromycin 10%
• Trimethoprim-sulfamethoxazole (TMP-SMX) 10%
• Lamivudine 10%
• Concomitant Therapy 10%
• Central Nervous System Lesions 10%
• Oral Thrush 10%
• Esophageal Candidiasis 10%
• CYP2C19 10%
• Pulmonary Aspergillosis 10%
• Naranjo 10%
• Enfuvirtide 10%
• Probability Scale 10%
• Concentration Monitoring 10%

Immunology and Microbiology

• Candida 100%
• Drug Interaction 100%
• Systemic Lupus Erythematosus 50%
• Breakthrough Infection 50%
• Human Immunodeficiency Virus Infection 50%
• Blood Level 50%
• Central Nervous System 50%
• Drug Megadose 50%
• Tenofovir 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Candidiasis 100%
• Voriconazole 100%
• Thrush 30%
• Phenytoin 20%
• Efavirenz 20%
• Drug Interaction 20%
• Infection 10%
• CYP2C9 10%
• CYP3A4 10%
• Human Immunodeficiency Virus Infection 10%
• Tenofovir 10%
• Cotrimoxazole 10%
• Lamivudine 10%
• CYP2C19 10%
• Esophagus Candidiasis 10%
• Lung Aspergillosis 10%
• Combination Therapy 10%
• Systemic Lupus Erythematosus 10%
• Azithromycin 10%
• Enfuvirtide 10%